Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 30;7(2):104–111. doi: 10.1093/ehjcvp/pvaa004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Subgroup analyses: risk of major adverse cardiovascular events among users vs. non-users of GLP-1 receptor agonist by age, sex, ST-segment elevation myocardial infarction (STEMI), and estimated glomerular filtration rate category. CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; P-value int., P-value of interaction; STEMI, ST-segment elevation myocardial infarction. Model adjusted for (when relevant): age, sex, smoking, body mass index, estimated glomerular filtration rate category, comorbidities (heart failure, cancer, hypertension, percutaneous coronary intervention, coronary artery bypass grafting, stroke, peripheral vascular disease, atrial fibrillation, Killip, ST-segment elevation myocardial infarction), and cardiovascular medications (aspirin, statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, P2Y12 inhibitors).